Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Dent, Rebecca A × Lindeman, Geoffrey J Clemons, Mark Wildiers, Hans Chan, Arlene McCarthy, Nicole J Singer, Christian F Lowe, Elizabeth S Watkins, Claire L Carmichael, James #
Biomed Central Ltd
Breast Cancer Research vol:15 issue:5
This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).